Clinical trialPhase 2Recruiting
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
- Outcome
- Ongoing
- Phase
- Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- 1 April 2024
- Expected end
- 1 March 2028
- Enrollment
- 30 participants
- Sites
- 1
- Primary outcomes
- progression-free survival, PFS
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 August 2025
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 4
- Registry-listed results paperPancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics. DOI 10.1097/sla.0000000000006168↗
- BackgroundPotential Biomarkers in Lewis Negative Patients With Pancreatic Cancer. DOI 10.1097/sla.0000000000001741↗
- BackgroundPatients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. DOI 10.3892/ol.2016.5501↗
- BackgroundCA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. DOI 10.1016/j.canlet.2016.10.046↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.